GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albert Labs International Corp (XCNQ:ABRT) » Definitions » DeferredTaxAndRevenue

Albert Labs International (XCNQ:ABRT) DeferredTaxAndRevenue : C$0.00 Mil (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Albert Labs International DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Albert Labs International's current deferred tax and revenue for the quarter that ended in Sep. 2023 was C$0.00 Mil.

Albert Labs International DeferredTaxAndRevenue Historical Data

The historical data trend for Albert Labs International's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albert Labs International DeferredTaxAndRevenue Chart

Albert Labs International Annual Data
Trend Dec21 Dec22
DeferredTaxAndRevenue
- -

Albert Labs International Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Albert Labs International DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Albert Labs International's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Albert Labs International Business Description

Traded in Other Exchanges
N/A
Address
6996, Merritt Avenue, Burnaby, BC, CAN, V5J 4R6
Albert Labs International Corp is a laboratory-based, clinical research and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of clinical pathway.

Albert Labs International Headlines

No Headlines